MedPath

Impact of Fluocinonide 0,05% in Oral Lichen Planus

Not Applicable
Recruiting
Conditions
Oral Lichen Planus
Interventions
Registration Number
NCT06135805
Lead Sponsor
University of Catania
Brief Summary

A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of Fluocinonide 0,05% and determinate the statistical significance of the outcome variables. Oral cavity lichen is a chronic inflammatory condition affecting the mucosa of the oral cavity , which significantly reduces the quality of life of affected individuals.

Detailed Description

A double-blind placebo-controlled study was conducted to evaluate the clinical efficacy of Fluocinonide 0.05% oral gel and determine the statistical significance of outcome variables.

20 patients with Oral Lichen Planus were divided by a randomization system, into two groups: case group treated with Fluocinonide 0.05% oral gel and applied to oral lesions 2 times a day for 1 month and a placebo group as a control group; with 2 months of follow-up.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • Clinical and histologic diagnosis of Lichen Planus Orale;
  • Presence of symptoms related to Lichen Planus Orale;
  • Clinical follow-up period of at least 12 weeks;
  • Acceptance of informed consent
Exclusion Criteria
  • State of pregnancy or lactation; h
  • Histologic signs of dysplasia;
  • Medications that induce a lichenoid response (ACE inhibitors, β-blockers, etc.);
  • Presence of amalgam fillings in the vicinity of lesions;
  • Treatment of oral lichen in the previous 6 months from the start of the program;
  • Presence of extraoral lesions (genital, skin, etc.);
  • Diabetes being treated with oral hypoglycemic drugs;
  • History of previous immunodeficiency;
  • HIV seropositivity;
  • Previous allogeneic bone marrow transplantation;
  • Diagnosis of LES or other autoimmune disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Active Comparator: Fluocinonide 0,,05% oral gelFluocinonide 0,05% oral gelPatients were treated with a topical gel of Fluocinonide 0.05%, applied to oral lesions twice daily for 1 month.
Placebo Comparator: PlaceboPlaceboPatients were treated with a topical gel of placebo, applied to oral lesions twice daily for 1 month.
Primary Outcome Measures
NameTimeMethod
Assessment of sings3 months

Assessment of sings using the Thongprasom scoring system at baseline and after 2 months

Secondary Outcome Measures
NameTimeMethod
Assessment of symptoms3 months

Assessment of symptoms using the VAS scale at baseline and after 2 months

Trial Locations

Locations (1)

AOU Policlinico G. Rodolico

🇮🇹

Catania, Italy

© Copyright 2025. All Rights Reserved by MedPath